JP7857666B2 - 糖尿病に対する低用量の肝細胞増殖因子遺伝子治療 - Google Patents
糖尿病に対する低用量の肝細胞増殖因子遺伝子治療Info
- Publication number
- JP7857666B2 JP7857666B2 JP2022563827A JP2022563827A JP7857666B2 JP 7857666 B2 JP7857666 B2 JP 7857666B2 JP 2022563827 A JP2022563827 A JP 2022563827A JP 2022563827 A JP2022563827 A JP 2022563827A JP 7857666 B2 JP7857666 B2 JP 7857666B2
- Authority
- JP
- Japan
- Prior art keywords
- hgf
- dose
- administration
- promoter
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020192844 | 2020-11-19 | ||
| JP2020192844 | 2020-11-19 | ||
| JP2021145795 | 2021-09-07 | ||
| JP2021145795 | 2021-09-07 | ||
| PCT/JP2021/042463 WO2022107853A1 (ja) | 2020-11-19 | 2021-11-18 | 糖尿病に対する低用量の肝細胞増殖因子遺伝子治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2022107853A1 JPWO2022107853A1 (cg-RX-API-DMAC7.html) | 2022-05-27 |
| JPWO2022107853A5 JPWO2022107853A5 (cg-RX-API-DMAC7.html) | 2023-10-24 |
| JP7857666B2 true JP7857666B2 (ja) | 2026-05-13 |
Family
ID=81707991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563827A Active JP7857666B2 (ja) | 2020-11-19 | 2021-11-18 | 糖尿病に対する低用量の肝細胞増殖因子遺伝子治療 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230414718A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4249003A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7857666B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022107853A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6711495B1 (ja) | 2019-05-27 | 2020-06-17 | 株式会社ナイスリー | 車両用盗難防止装置 |
| JP7040806B2 (ja) | 2020-03-17 | 2022-03-23 | 株式会社オリンピア | 遊技機 |
-
2021
- 2021-11-18 JP JP2022563827A patent/JP7857666B2/ja active Active
- 2021-11-18 EP EP21894725.7A patent/EP4249003A4/en active Pending
- 2021-11-18 WO PCT/JP2021/042463 patent/WO2022107853A1/ja not_active Ceased
- 2021-11-18 US US18/253,651 patent/US20230414718A1/en active Pending
Non-Patent Citations (7)
| Title |
|---|
| Circulation,2003年,Vol. 107, No. 19,p. 2499-2506 |
| EXPERIMENTAL and MOLECULAR MEDICINE,2003年,Vol. 35, No. 6,p. 494-500 |
| Gene,1991年,Vol. 108, No. 2,p. 193-200 |
| Korean J Physiol Pharmacol,2003年,Vol. 7,p. 261-266 |
| Life Sciences,2021年03月,Vol. 268, No. 119014,p. 1-5 |
| Nephron Physiology,2006年,Vol. 102,p. 92-102 |
| ウイルス,2003年,Vol. 53, No. 2,p. 147-153 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022107853A1 (ja) | 2022-05-27 |
| JPWO2022107853A1 (cg-RX-API-DMAC7.html) | 2022-05-27 |
| EP4249003A4 (en) | 2024-10-23 |
| US20230414718A1 (en) | 2023-12-28 |
| EP4249003A1 (en) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11975078B2 (en) | Muscle-specific nucleic acid regulatory elements and methods and use thereof | |
| JP2023144087A (ja) | 組換えGlut1アデノ随伴ウイルスベクターコンストラクトおよびGlut1発現を回復させる方法 | |
| JP2025063034A (ja) | ライソゾーム病の遺伝子治療 | |
| JP2004500880A (ja) | 肝臓特異的な遺伝子発現カセット、及びその使用法 | |
| KR20220107243A (ko) | Apoe 유전자 요법 | |
| CN104936606A (zh) | 糖原贮积病的基因疗法 | |
| US6410011B1 (en) | Gene therapy for restenosis using an adenoviral vector | |
| JP7287611B2 (ja) | 改良型アデノ随伴ウイルスベクター | |
| KR20160137908A (ko) | 당뇨병-연관 심기능 장애 및 울혈성 심부전을 치료하기 위한 우로코르틴-2 및 연관 유전자들을 인코딩하는 바이러스 벡터들의 전신 전달 | |
| JP2022511227A (ja) | Igf-1異型体を発現させるdnaコンストラクトを用いた神経病症の治療 | |
| US20240173381A1 (en) | Hb-egf gene therapy for diabetes | |
| US20100184838A1 (en) | Compositions and methods for retinal transduction and photoreceptor specific transgene expression | |
| US20160144055A1 (en) | Gene therapy vector for treatment of steroid glaucoma | |
| US20230414718A1 (en) | Low-dose hepatocyte growth factor gene therapy for diabetes | |
| HK40095489A (en) | Low-dose hepatocyte growth factor gene therapy for diabetes | |
| RU2853169C2 (ru) | Генотерапия с использованием hb-egf для лечения диабета | |
| CN116685340A (zh) | 针对糖尿病的低剂量的肝细胞生长因子基因治疗 | |
| HK40103669A (en) | Hb-egf gene therapy for diabetes | |
| US20230101788A1 (en) | Gene therapy | |
| CN117279670A (zh) | 用于糖尿病的hb-egf基因治疗 | |
| US20020031493A1 (en) | Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf) | |
| US20260041794A1 (en) | Expression cassette for target gene and use thereof | |
| US12281323B2 (en) | Treatment for restoring ureagenesis in carbamoyl phosphate synthetase 1 deficiency | |
| HK40104471A (en) | Expression cassettes for target genes and their applications | |
| TW202521698A (zh) | 用於目標基因的表現匣及其應用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A5211 Effective date: 20230407 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20230517 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230517 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231016 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241107 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260108 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260407 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260420 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7857666 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |